Clinical trials: Malignant Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study
This phase Ib trial tests the safety, side effects, and best dose of STI-3031 given directly into the into the lymph nodes or the lymph vessels (intra-lymphatic) using the Sofusa DoseConnect device in treating patients with…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma, Recurrent Metastatic Melanoma
- Trial name
- NCT05393713
- Testing
- Anti-PD-L1 Monoclonal Antibody IMC-001, Punch Biopsy
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Malignant Melanoma Stage III, Malignant Melanoma Stage IV
Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma
The CTLA-4 blocking monoclonal antibody ipilimumab (MDX-010, BMS-734016), has demonstrated anti-tumor activity in a subgroup of patients with Stage III (unresectable) or Stage IV melanoma (measurable per modified WHO criteria)…
- Trial name
- TriMix-Ipi (NCT01302496)
- Testing
- TriMix-DC and ipilimumab
- Where
- Belgium
- Volunteers
- 39 people
- Sponsor
- Bart Neyns
Melanoma, Stage I, Melanoma Stage III
Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors
This is a prospective, multi-centred cohort study whereby the EUNASS Study questionnaire will be administered electronically to identify needs of melanoma survivors, the extent to which these needs are being met, and identify…
- Conditions
- Melanoma, Stage I, Melanoma Stage III, Melanoma, Stage II
- Trial name
- EUNASS (NCT04675346)
- Testing
- Questionnaire
- Where
- United Kingdom
- Volunteers
- 252 people
- Sponsor
- Oxford University Hospitals NHS Trust
Metastatic Uveal Melanoma
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
This Phase 2 study evaluates the efficacy and safety of sequential treatment with percutaneous hepatic perfusion (PHP) using melphalan/HDS followed by tebentafusp in patients with metastatic uveal melanoma (mUM) with isolated…
- Trial name
- NCT07276386
- Testing
- Melphalan/HDS (Percutaneous Hepatic Perfusion), Tebentafusp
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Melanoma Stage III, Melanoma Stage IV
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
- Trial name
- NCT04139902
- Testing
- Dostarlimab (TSR-042) (singly), Dostarlimab (TSR-042) and TSR-022 (combination)
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Diwakar Davar
Tumor, Metastatic Melanoma
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
The goal of this clinical research study is to find the recommended dose of OBX-115 in combination with acetazolamide that can be given to patients with metastatic melanoma previously treated with immune checkpoint inhibitors.
- Conditions
- Tumor, Metastatic Melanoma, Melanoma
- Trial name
- NCT05470283
- Testing
- OBX-115, Acetazolamide, Cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
IVAC MUTANOME Phase I Clinical Trial
Clinical first-in-human study evaluating the safety, tolerability and immunogenicity of intra-nodal administration of a personalized vaccination with IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002…
- Trial name
- NCT02035956
- Testing
- IVAC MUTANOME, RBL001/RBL002
- Where
- 3 sites in Austria, Germany
- Volunteers
- 15 people
- Sponsor
- BioNTech RNA Pharmaceuticals GmbH
Melanoma
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
You are being asked to take part in this study because you have metastatic (cancer that has spread) melanoma. The goal of Part 1 of this clinical research study is to find the highest tolerable dose of APX005M that can be given…
- Trial name
- NCT02706353
- Testing
- APX005M, Pembrolizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Melanoma, Stage IV Skin Melanoma
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
This randomized phase II trial is studying how well giving vaccine therapy together with or without recombinant interleukin-12 followed by daclizumab works in treating patients with melanoma that has spread to other places in the…
- Trial name
- NCT01307618
- Testing
- NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Non Small Cell Lung Cancer
Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors
This is a prospective observational study of vaccine efficacy and safety in adult patients with malignancies (melanoma/Hodgkin's lymphoma/Non-small cell lung cancer).
- Trial name
- SPICE (NCT03989050)
- Where
- 2 sites in Germany
- Sponsor
- University of Cologne
Skin Cancer, Melanoma
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
Background: Adoptive cell therapy involves taking white blood cells called lymphocytes from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient to allow the cells to…
- Conditions
- Skin Cancer, Melanoma, Metastatic Melanoma
- Trial name
- NCT01118091
- Testing
- Aldesleukin, CD8 enriched Young TIL
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma, Stage IIIA Melanoma
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
This phase II trial studies how well high-dose aldesleukin and ipilimumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT02203604
- Testing
- aldesleukin, ipilimumab, laboratory biomarker analysis
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- CINJRegulatory
Prostatic Neoplasms, Breast Neoplasms
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR The goals of this study are to improve adherence to oral chemotherapeutic medications and self-management of symptoms among cancer patients.
- Conditions
- Prostatic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Melanoma
- Trial name
- NCT02043184
- Testing
- Interactive Voice Response (IVR) Reminders
- Where
- 8 sites in United States
- Volunteers
- 322 people
- Sponsor
- Michigan State University
Educational Problems, Melanoma (Skin)
Passive Versus Active Educational Interventions for Melanoma Recognition
This study evaluates the efficacy of a passive versus an active educational intervention in increasing the ability of laypersons at low risk for melanoma development, in recognizing atypical skin melanocytic lesions.
- Trial name
- PAMela (NCT04507048)
- Testing
- Active educational intervention, Passive educational intervention
- Where
- 7 sites in Italy
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Metastatic Cancer
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient's specific tumour type.
- Trial name
- MODULATE (NCT03009058)
- Testing
- IMM-101, Gemcitabine, Nab-paclitaxel
- Where
- 4 sites in France, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Immodulon Therapeutics Ltd
Advanced Melanoma
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, Metformin.
- Trial name
- NCT03311308
- Testing
- Pembrolizumab Injection [Keytruda], Metformin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Yana Najjar
Melanoma
Targeted Intervention for Melanoma Prevention
In this study, the researchers will conduct interviews with melanoma patients to describe the sun exposure and sun protection practices of patients and their children.
- Trial name
- NCT00394134
- Testing
- Interview
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- M.D. Anderson Cancer Center
Skin Cancer
A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions
The incidence of malignant melanoma has increased dramatically in recent decades. In 1930, the lifetime risk of an individual in the United States developing melanoma was 1 in 1,500.
- Trial name
- NCT00633516
- Testing
- Optical Spectroscopy
- Where
- 2 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.